- Home
- AMS vs GOVX Comparison
AMS vs GOVX Comparison
Compare AMS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- GOVX
- Stock Information
- Founded
- AMS 1980
- GOVX 2001
- Country
- AMS United States
- GOVX United States
- Employees
- AMS N/A
- GOVX N/A
- Industry
- AMS Medical Specialities
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- GOVX Health Care
- Exchange
- AMS Nasdaq
- GOVX Nasdaq
- Market Cap
- AMS 17.2M
- GOVX 16.8M
- IPO Year
- AMS N/A
- GOVX N/A
- Fundamental
- Price
- AMS $2.44
- GOVX $0.58
- Analyst Decision
- AMS
- GOVX Strong Buy
- Analyst Count
- AMS 0
- GOVX 3
- Target Price
- AMS N/A
- GOVX $10.67
- AVG Volume (30 Days)
- AMS 101.9K
- GOVX 1.1M
- Earning Date
- AMS 11-12-2025
- GOVX 11-11-2025
- Dividend Yield
- AMS N/A
- GOVX N/A
- EPS Growth
- AMS N/A
- GOVX N/A
- EPS
- AMS N/A
- GOVX N/A
- Revenue
- AMS $29,251,000.00
- GOVX $6,143,044.00
- Revenue This Year
- AMS $5.06
- GOVX N/A
- Revenue Next Year
- AMS N/A
- GOVX N/A
- P/E Ratio
- AMS N/A
- GOVX N/A
- Revenue Growth
- AMS 26.61
- GOVX 1943.07
- 52 Week Low
- AMS $2.27
- GOVX $0.43
- 52 Week High
- AMS $3.59
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- AMS 48.23
- GOVX 38.26
- Support Level
- AMS $2.45
- GOVX $0.54
- Resistance Level
- AMS $2.58
- GOVX $0.59
- Average True Range (ATR)
- AMS 0.14
- GOVX 0.04
- MACD
- AMS 0.01
- GOVX -0.00
- Stochastic Oscillator
- AMS 15.28
- GOVX 40.38
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.